65,437 trials
Hepatitis C Virus (HCV)
Primary: Steady-state Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Glecaprevir — 4790; 7870; 6860; 7520 ng*h/mL
Glaucoma · Endothelial Cell Loss, Corneal
Primary: Endothelial Cell Count Change — 2; -1; 0; -4 % change compared to baseline
Schizophrenia · Serious Mental Illness
Primary: Clinical Assessment Interview for Negative Symptoms Motivation & Pleasure Scale (CAINS MAP) - 12 Weeks — 19.8; 17.3; 17.4; 17.1 score on a scale — p=0.295
Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Schizophrenia · Schizoaffective Disorder
Primary: Visual Attention to Static Faces — 0.54; 0.52; 0.57; 0.53 proportion of time attending to AOIs
Central Venous Catheter Thrombosis · Central Venous Catheter Associated Bloodstream Infection
Primary: Catheter-associated Venous Thrombosis — 3; 3 Participants
GDM · Insulin Resistance · Glucose Intolerance
Primary: Short-term Effect of Fertility Medications on Glucose Homeostasis and Insulin Resistance in Patients Undergoing IVF Treatment — 87.62; 82.19; 9.37; 9.45 mg/dL
Herpes Labialis
Primary: Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's Assessment — 21.8; 16.4; 19.9; 78.2 percentage of partcipants…
Osteoarthritis, Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Domain Score at Week 2 — -3.64; -3.15 Units on a scale — p=0.39
Herpes Simplex Type 2
Primary: Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 6 to 13) — 13.53 percentage change
Psoriasis
Primary: Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16 — 65.6; 73.8 percentage of participants
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants
Recurrent Pericarditis
Primary: Time to Pericarditis Recurrence in the RW Period — NA; 8.6 weeks — p=<0.0001
Age-Related Macular Degeneration
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 24 — 4.35; 0.87; -1.70 letters
Influenza Immunization · Healthy Volunteers
Primary: Number of Participants Aged 6 Months to <9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2 — 29; 31; 15; 30 Participants